Targeted radiopharmaceutical therapy of liver cancer with alpha-particle
Active Project Grant Awarded Last action
- Award ID
- HT9425261E299
- Recipient
-
Case Western Reserve University UEI HJMKEF7EJW69
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,399,977
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 9% complete
- Place of performance
- Cleveland, OH 44106, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded Case Western Reserve University $1,399,977 on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct targeted radiopharmaceutical therapy of liver cancer with alpha-particle treatment. The award funds research through July 31, 2029, with place of performance in Cleveland, Ohio. Case Western Reserve University's Office of Research Administration, operating in affiliation with University Hospitals of Cleveland, serves as the prime recipient. The program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative solutions for battlefield medical challenges and related conditions.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The Cleveland Clinic Foundation | $74,799 |
Quick answers
Who received award HT9425261E299?
HT9425261E299 was awarded to Case Western Reserve University by Defense Health Agency (Department of Defense) on August 1, 2026.
How much is award HT9425261E299 worth?
$1,399,977 has been obligated on HT9425261E299.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award